Lack of lipotoxicity effect on β-cell dysfunction in ketosis-prone type 2 diabetes

Diabetes Care

Volumn 33, Issue 3, 2010, Pages 626-631

  Umpierrez, Guillermo E ^a   Smiley, Dawn ^a   Robalino, Gonzalo ^a   Peng, Limin ^b   Gosmanov, Aidar R ^a   Kitabchi, Abbas E ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C PEPTIDE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTRALIPID; ISOPHANE INSULIN; LIPID;

ADULT; AFRICAN AMERICAN; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN INFUSION; INSULIN RELEASE; INSULIN RESPONSE; INSULIN TREATMENT; KETOSIS PRONE NON INSULIN DEPENDENT DIABETES MELLITUS; LIPOTOXICITY; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; REMISSION; STIMULATION; TOXICITY;

ADULT; ARGININE; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; DRUG ADMINISTRATION SCHEDULE; FAT EMULSIONS, INTRAVENOUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; OBESITY; PANCREATIC FUNCTION TESTS; REMISSION INDUCTION; WITHHOLDING TREATMENT;

EID: 77649257053     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1369     Document Type: Article

References (25)

1. Umpierrez GE, Casals MM, Gebhart SP, Mixon PS, Clark WS, Phillips LS. Diabetic ketoacidosis in obese African-Americans. Diabetes 1995;44:790-795
2. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus.AnnInternMed2006;144:350-357
3. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev 2008;29: 292-302
4. Banerji MA, Chaiken RL, Huey H, Tuomi T, Norin AJ, Mackay IR, Rowley MJ, Zimmet PZ, Lebovitz HE. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4: flatbush diabetes. Diabetes 1994;43:741-745
5. Umpierrez GE, Woo W, Hagopian WA, Isaacs SD, Palmer JP, Gaur LK, Nepom GT, Clark WS, Mixon PS, Kitabchi AE. Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. Diabetes Care 1999;22:1517-1523
6. Mauvais-Jarvis F, Sobngwi E, Porcher R, Riveline JP, Kevorkian JP, Vaisse C, Charpentier G, Guillausseau PJ, Vexiau P, Gautier JF. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of β-cell dysfunction and insulin resistance. Diabetes 2004;53:645-653
7. Maldonado M, Hampe CS, Gaur LK, D'Amico S, Iyer D, Hammerle LP, Bolgiano D, Rodriguez L, Rajan A, Lernmark A, Balasubramanyam A. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab 2003;88:5090-5098
8. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Nearnormoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001;18:10-16
9. Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006;29:2739-2748
10. van Haeften TW, Voetberg GA, Gerich JE, van der Veen EA. Dose-response characteristics for arginine-stimulated insulin secretion in man and influence of hyperglycemia. J Clin Endocrinol Metab 1989; 69:1059-1064
11. Umpierrez GE, Smiley D, Robalino G, Peng L, Kitabchi AE, Khan B, Le A, Quyyumi A, Brown V, Phillips LS. Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in obese African-Americans with type 2 diabetes. J Clin Endocrinol Metab 2009;94: 609-614
12. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-2474
13. Unger RH, Zhou YT. Lipotoxicity of β-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001; 50(Suppl. 1):S118-S121
14. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994;93:870-876
15. Yoshikawa H, Tajiri Y, Sako Y, Hashimoto T, Umeda F, Nawata H. Effects of free fatty acids on beta-cell functions: a possible involvement of peroxisome proliferator-activated receptors alpha or pancreatic/duodenal homeobox. Metabolism 2001;50:613- 618
16. Jacqueminet S, Briaud I, Rouault C, Reach G, Poitout V. Inhibition of insulin gene expression by long-term exposure of pancreatic beta cells to palmitate is dependent on the presence of a stimulatory glucose concentration. Metabolism 2000;49:532-536
17. Gremlich S, Bonny C, Waeber G, Thorens B. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem 1997;272:30261-30269
18. Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF. Prolonged elevation of plasma free fatty acids impairs pancreatic β-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 2000;49: 399-408
19. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 1999;276:E1055-E1066
20. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53:2079-2086
21. Kahn SE. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-4058
22. Halter JB, Graf RJ, Porte D Jr. Potentiation of insulin secretory responses by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for imparied glucose potentiation. J Clin Endocrinol Metab 1979;48:946-954
23. Poitout V, Briaud I, Kelpe C, Hagman D. Gluco-lipotoxicity of the pancreatic beta cell. Ann Endocrinol (Paris) 2004;65: 37-41
24. Briaud I, Kelpe CL, Johnson LM, Tran PO, Poitout V. Differential effects of hyperlipidemia on insulin secretion in islets of Langerhans from hyperglycemic versus normoglycemic rats. Diabetes 2002;51: 662-668
25. Waitzberg DL, Torrinhas RS, Jacintho TM. New parenteral lipid emulsions for clinical use. J Parenter Enteral Nutr 2006; 30:351-367